Editorial

Plasmapheresis in Lupus
The term apheresis derives from the Greek 'to take by force'. Coined by Abel, Rowntree and Turner in 1914 when these Johns Hopkins pharmacologists were studying artificial kidneys, apheresis has had a checkered and misunderstood journey over the last 79 years'. The separation of blood components was performed in a tedious, manual fashion when Michael Rubenstein's group at Cedars-Sinai Medical Center in Los Angeles saved the life of a young boy with thrombotic thrombocytopenic purpura in 1959'. When this was followed up with additional promising case reports, the National Cancer Institute adapted the Cohn centrifuge (first marketed in 1953) to mechanically separate whole blood into red cells, platelets, leukocytes and plasma by taking advantage of their differing cell density gradients. First marketed in the late 1960s using a modified dairy creamer separator technology, apheresis devices are primarily used for donor purposes.
What is the rationale for attempting apheresis in SLE 31 Plasma contains immunoglobulins, complement and autoantibodies known to be pro-inflammatory. Removal of these proteins might decrease the inflammatory process or modulate immune interactions. Plasmapheresis alters the equilibrium between free and bound immune complexes and reverses reticuloendothelial system blockade in order to allow their clearance. Bacterial killing is also improved.
Interest in using apheresis for rheumatic diseases did not surface until the mid-19'7lls when John Verrier Jones and his colleagues in the UK undertook several bold and innovative trials in lupus patients. Jones' keen clinical judgement and powers of observation were summarized in his landmark 1982 publication which expressed the state of the art at that time'. In essence, if performed correctly plasmapheresis (the removal of plasma on a cell separator centrifugation device and its replacement with albumin and saline) was of no value if the patient had mild disease or was on no concurrent medication or was taking steroids alone. Plasmapheresis was modestly beneficial if azathioprine was also administered and seemed to have its best results in acutely ill patients with high levels of circulating immune complexes who were also placed on concurrent oral cyclophosphamide. What do we mean by 'performed correctly'? The efficacy of a plasmapheresis trial takes into account certain inherent variables and all too often the trial is faultily designed and a negative result becomes a self-fulfilling prophecy (discussed in detail in reference 5). First of all, at least 95 % native plasma must be exchanged and plasma kinetics mandate at least a 40 ml/ kg exchange three times a week for 3 weeks or its equivalent (e.g. 60 ml/kg exchange daily for 6 days). Second, with the exception of thrombotic thrombocytopenic purpura albumin is used as opposed to plasma as a replacement product. Third, the concept of antibody rebound needs to be considered in any protocol. Simply stated, antibody rebound implies that removing plasma proteins in a patient with active disease stimulates the liver to promote the synthesis of those proteins at a rate greater than which they are removed. The antibody rebound phenomenon is limited to patients with active inflammatory processes and is not observed in healthy plasma donors. For example, an IgG of 600mg/dl prepheresis doubles to 1200 mg/dl within days if the patient is not on a cytotoxic drug to suppress its formation. Certain proteins are more intravascular than others. It is easier to remove IgM (which is two-thirds intravascular) than IgG (one-half intravascular). It is also surprising how many silly study design mistakes have resulted in negative trials. These included giving the patient their morning steroid dose prior to apheresis, which was then pheresed out. At least two rheumatoid arthritis controlled trials provided their patients with hospitalization and bedrest which of course was independently efficacious. A recent controlled trial of plasmapheresis for inflammatory myositis did not use any concurrent immunosuppression and therefore guaranteed negative results 6.
By the early 1980s the publication of case reports using plasmapheresis for serious lupus diminished.
Controlled trials were now necessary to determine the efficacy of plasmapheresis in lupus and for its various complications. A Canadian cooperative trial assured plasmapheresis a place in managing thrombotic thrombocytopenic purpura' and the ability of apheresis to manage cryoglobulinemia and hyperviscosity syndrome (which are occasionally seen in SLE) was beyond double
The focus of a controlled trial should be in areas where clear-cut measurements of disease activity could be serially followed (e.g. renal disease as opposed to central nervous system lupus) and cytotoxic drug therapy was not as effective as desired. In view of the expense of apheresis (up to $5000 per procedure), the goal of any protocol would be to show that a single course of 9-20 treatments would not have to be repeated and is superior to conventional management. Apheresis is relatively safe, with only a 3 % incidence of serious complications in acutely ill patients 8.
As a result, a multicenter lupus nephritis protocol was begun in the early 1980's and its results published last year 9. As originally designed, newly diagnosed patients with proliferative disease were randomized to receive either prednisone and oral cyclophosphamide with or without plasmapheresis. The results demonstrated improvements in both groups and no significant differences were noted. Does this mean than plasmapheresis has no place in lupus nephritis as some practitioners have suggested? What about the individual case reports documenting dramatic improvements in certain circumstances? Our group had several concerns about this studs 10. First of all, statisticians had told some of the investigators that 200 patients had to be entered in order to show significant results, but only 86 were ultimately studied in 14 centers. Several rheumatologists, unfamiliar with apheresis, treated patients who inadvertantly had their steroids 'pheresed out' (personal communication). Newly diagnosed lupus nephritis patients will generally have a favourable initial response to prednisone and cyclophosph ide and comparing two effective arms of a protocol makes it difficult to show differences between them. Our group received funding to study the addition of plasmapheresis in patients resistant to cytotoxic therapy. In other words, when cyclophosphamide fails to control proliferative nephritis should apheresis be added? Twenty-seven patients, 17 of whom were randomized, were followed and the benefits of plasmapheresis in this subgroup were documented&dquo;. Conventional centrifugation plasmapheresis is only one method for performing apheresis which might be applicable for SLE. Centrifugation devices are also capable of removing lymphocytes. The rationale for this stems from the efficacy of lympholytic drugs such as corticosteroids and cytotoxics. Lymphocytes can also be removed via external devices with thoracic duct drainage and total lymphoid irradiation. Unfortunately, several factors have precluded lymphocytapheresis from being effective in SLE. These include: (1) peripheral lymphocytes have only 30-60 % long-lived populations compared with close to 80 % in the thoracic duct, (2) normal cardiovascular functioning is imperative as 15 0/0 of the blood volume must be extracorporeal in order to achieve an effective lymphocyte cut, and (3) as most seriously active lupus patients are on concurrent corticosteroids and cytotoxic therapy and have antilympho-cyte antibodies the numbers of lymphocytes removed at a pass is disappointingly low.
Hans Euler and his colleagues in Kiel have proposed a challenging concept which deliberately exploits antibody rebound. His 'pulse-synchronization' protocol was perfected in animal studies and involves plasmapheresing a critically ill lupus patient who has not had a cytotoxic drug in at least 4 weeks. After inducing antibody rebound with three daily plasma exchanges, the patient is given a high dose of parenteral cyclophosphamide which eliminates the larger than usual number of circulating memory lymphocytes, autoantibodies and other inflammatory mediators. Initial reports have been promising and an international controlled trial is in progress 12,13 .
As dialysis technology advanced, membranes capable of removing plasma were introduced. This was followed by the development of secondary membranes which could selectively remove anti-DNA, immune complexes or certain plasma fractions 14, &dquo;. The theoretical advantage of selective plasmapheresis includes lower costs because expensive albumin replacement is not needed.
However, membranes are not biologically inert and can activate complement and occasionally induce hemolysis. Also, it is uncertain which putative autoantibody's removal is desirable. Other apheresis technologies are being studied. Photopheresis involves exposing leukocytes on-line to ultraviolet'A light in the presence of 8-methoxypsoralen in an effort to suppress pathogenic T cell clones&dquo;. Its use in SLE is investigational and controversial in view of its use of ultraviolet light.
As of this writing, plasmapheresis using a membrane or centrifuge separator is indicated as an acute inter.vention for cryoglobulinemia, hyperviscosity and thrombotic thrombocytopenic purpura complications of SLE. Short-term plasmapheresis may be a useful adjunct for managing life-threatening complications such as fulminant vasculitis or central nervous system '~ disease along with corticosteroids and cytotoxic agents. Patients with organ-threatening disease resistant to corticosteroids and cytotoxic agents such as proliferative nephritis or autoimmune hemolytic anemia may benefit from plasmapheresis. Even though some controlled trials show no 'averaged' benefit, we are all aware of individual patients who have turned around with plasma exchange after failing conventional therapy. Plasmapheresis deserves further study for removing anticardiolipin antibody in pregnant patients with previous miscarriages in whom steroids or heparin is undesirable &dquo; and for transiently raising platelet counts in patients with idiopathic thrombocytopenic purpura so that they can safely undergo a splenectomy 19. Finally, apheresis technology is rapidly advancing. In the next few years, columns will be able to remove lymphocyte subpopulations online or directly provide them with anti-inflammatory Daniel J. Wallace Cedars-Sinai Medical Center, UCLA School of Medicine, Los Angeles, CA 90048, USA medications. Improved membranes will be able to adsorb out just about any autoantibody we program it to. Rheumatologists have not heard the last from apheresis!
